Immunomedics

Immunomedics was founded in July 1982 by David M. Goldenberg.^[2]

Michael Pehl was named CEO in December 2017 but left for personal reasons in February 2019.^[3] At that time, Dr. Behzad Aghazadeh was named Executive Chairman.^[4]

In October 2020, Gilead Sciences acquired the company.^[1] In March 2022, Gilead announced the closing of the former Immunomedics facility in Morris Plains.^[5]

• Epratuzumab is a humanized anti-CD22 monoclonal antibody in phase III trials for pediatric leukemia.^{[citation needed]}
• Sacituzumab govitecan (IMMU-132 / Trodelvy) is an anti-Trop-2-SN-38 antibody-drug conjugate for breast cancer and solid tumors. It was approved in April 2020 by the FDA for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease.^[6] In 2017, the company scrapped a licensing deal for the drug with Seagen that led to the resignation of founder David M. Goldenberg.^[7]
• Labetuzumab (IMMU-130) is an anti-CEACAM5-SN-38 antibody-drug conjugate in clinical trials for colorectal cancer.^{[citation needed]}
• Veltuzumab is an anti-CD20 monoclonal antibody for treatment of cancer.^{[citation needed]}
• Milatuzumab (IMMU-110) is an anti-CD74 monoclonal antibody for autoimmune diseases.^{[citation needed]}
• IMMU-114 is an anti-HLA-DR for hematological cancers.^[8]